2024 Q2 Form 10-Q Financial Statement

#000165495424006412 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $510.9K $399.6K
YoY Change -30.69% -29.64%
% of Gross Profit
Research & Development $19.45K $19.45K
YoY Change -50.46% -73.63%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $530.3K $419.1K
YoY Change -31.69% -34.7%
Operating Profit -$419.1K
YoY Change -34.7%
Interest Expense -$72.72K $74.71K
YoY Change 57.98% 268.68%
% of Operating Profit
Other Income/Expense, Net -$59.01K
YoY Change -34.69%
Pretax Income -$603.0K -$478.1K
YoY Change -26.4% -34.7%
Income Tax
% Of Pretax Income
Net Earnings $27.11K -$478.1K
YoY Change -102.81% -34.7%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 188.2M shares 105.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.460K $8.250K
YoY Change -15.23% -82.35%
Cash & Equivalents $8.456K $8.247K
Short-Term Investments
Other Short-Term Assets $19.45K
YoY Change 11.14%
Inventory
Prepaid Expenses $19.45K
Receivables
Other Receivables
Total Short-Term Assets $8.456K $27.69K
YoY Change -15.29% -56.9%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $8.456K $27.69K
Total Long-Term Assets $0.00 $0.00
Total Assets $8.456K $27.69K
YoY Change -15.29% -56.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.095M $1.063M
YoY Change 29.45% 60.75%
Accrued Expenses $2.526M $2.346M
YoY Change 31.59% 44.4%
Deferred Revenue
YoY Change
Short-Term Debt $1.312M $1.327M
YoY Change -0.4% -25.27%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.157M $4.937M
YoY Change 20.97% 14.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.157M $4.937M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $5.157M $4.937M
YoY Change 20.97% 14.4%
SHAREHOLDERS EQUITY
Retained Earnings -$62.75M -$62.77M
YoY Change 4.81% 6.31%
Common Stock $21.40K $12.65K
YoY Change 616.34% 2162.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.149M -$4.910M
YoY Change
Total Liabilities & Shareholders Equity $8.456K $27.69K
YoY Change -15.29% -56.9%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $27.11K -$478.1K
YoY Change -102.81% -34.7%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$120.8K -$100.3K
YoY Change 69.74% -42.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 121.0K 100.1K
YoY Change 251.89% -47.31%
NET CHANGE
Cash From Operating Activities -120.8K -100.3K
Cash From Investing Activities
Cash From Financing Activities 121.0K 100.1K
Net Change In Cash 210.0 -230.0
YoY Change -100.57% -101.5%
FREE CASH FLOW
Cash From Operating Activities -$120.8K -$100.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
27693 usd
CY2023Q2 us-gaap Assets
Assets
9982 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
845502 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1371879 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
512621 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
548041 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1062823 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1833529 usd
CY2024Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
675924 usd
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
937576 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
55597779 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59869400 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4253314 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9982 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8247 usd
CY2024Q1 us-gaap Assets
Assets
27693 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
18084 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
19446 usd
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
23211 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
80707 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
650603 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
380013 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4937344 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4263296 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57836980 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62774599 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4909651 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27693 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001082733
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
48018 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
512542 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-25753
dei Entity Registrant Name
EntityRegistrantName
VISIUM TECHNOLOGIES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0449667
dei Entity Address Address Line1
EntityAddressAddressLine1
4094 MAJESTIC LANE
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 360
dei Entity Address City Or Town
EntityAddressCityOrTown
FAIRFAX
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
22033
dei City Area Code
CityAreaCode
703
dei Local Phone Number
LocalPhoneNumber
273-0383
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
188218508 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9982 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
9982 usd
CY2024Q1 vism Due From Officers Stockholders
DueFromOfficersStockholders
178633 usd
CY2023Q2 vism Due From Officers Stockholders
DueFromOfficersStockholders
99578 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
10984 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2024Q1 vism Notes Payable Net Of Discount
NotesPayableNetOfDiscount
14866 usd
CY2023Q2 vism Notes Payable Net Of Discount
NotesPayableNetOfDiscount
26805 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126480567 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126472250 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37199647 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29844713 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
12648 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2987 usd
CY2024Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
399604 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
567979 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1990912 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1461560 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19447 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73755 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67256 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175707 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
419051 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
641734 usd
us-gaap Operating Expenses
OperatingExpenses
2058168 usd
us-gaap Operating Expenses
OperatingExpenses
1637267 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-419051 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-641734 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2058168 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1637267 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
24807 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-50384 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
57496 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-84246 usd
CY2024Q1 vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
CY2023Q1 vism Derivative Liability Expense
DerivativeLiabilityExpense
4634 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
62773 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9106 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15068 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-21141 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-519993 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
74712 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
20265 usd
us-gaap Interest Expense
InterestExpense
253256 usd
us-gaap Interest Expense
InterestExpense
187205 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-59011 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90354 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-216901 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-854217 usd
CY2024Q1 vism Net Income Losses
NetIncomeLosses
-478062 usd
CY2023Q1 vism Net Income Losses
NetIncomeLosses
-732085 usd
vism Net Income Losses
NetIncomeLosses
-2275069 usd
vism Net Income Losses
NetIncomeLosses
-2491484 usd
CY2024Q1 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
145670 usd
CY2023Q1 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
0 usd
us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
630130 usd
us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
0 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-623732 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-732085 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2905199 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2491484 usd
CY2024Q1 vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.01
CY2023Q1 vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.16
vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.04
vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.72
CY2024Q1 vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
108132383 shares
CY2023Q1 vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
4658570 shares
vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
74327012 shares
vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
3454032 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4724913 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
111787 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
181537 usd
CY2024Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-478062 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4909651 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4253314 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
417887 usd
vism Shares Issued As Compensation To Employees Amount
SharesIssuedAsCompensationToEmployeesAmount
89407 usd
vism Shares Issued As Compensation To Directors And Officers Amount
SharesIssuedAsCompensationToDirectorsAndOfficersAmount
520624 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
590814 usd
us-gaap Dividends Common Stock
DividendsCommonStock
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-2275069 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4909651 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3997400 usd
CY2023Q1 vism Shares Issued As Compensation To Employees Amount
SharesIssuedAsCompensationToEmployeesAmount
71300 usd
CY2023Q1 vism Shares Issued As Compensation To Directors And Officers Amount
SharesIssuedAsCompensationToDirectorsAndOfficersAmount
161200 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
213418 usd
CY2023Q1 vism Commitment Shares Issued Pursuant To Financing Amount
CommitmentSharesIssuedPursuantToFinancingAmount
14000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-732085 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4251487 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2793558 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
36956 usd
vism Shares Issued As Compensation To Employees Amount
SharesIssuedAsCompensationToEmployeesAmount
144150 usd
vism Shares Issued As Compensation To Directors And Officers Amount
SharesIssuedAsCompensationToDirectorsAndOfficersAmount
361013 usd
vism Gains Losse On Extinguishment Of Debt
GainsLosseOnExtinguishmentOfDebt
186972 usd
vism Shares Issued For Conversion Of Notes Payable And Accrued Interest Amount
SharesIssuedForConversionOfNotesPayableAndAccruedInterestAmount
290464 usd
vism Commitment Shares Issued Pursuant To Financing Amount
CommitmentSharesIssuedPursuantToFinancingAmount
14000 usd
vism Shares Issued For Exercise Of Warrants Amount
SharesIssuedForExerciseOfWarrantsAmount
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-2491484 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4251487 usd
us-gaap Profit Loss
ProfitLoss
2275069 usd
us-gaap Profit Loss
ProfitLoss
2491484 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1027918 usd
us-gaap Share Based Compensation
ShareBasedCompensation
542149 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
32355 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
83218 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
62773 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
57496 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-84246 usd
vism Losses On Extinguishment Of Debt
LossesOnExtinguishmentOfDebt
-21141 usd
vism Losses On Extinguishment Of Debt
LossesOnExtinguishmentOfDebt
-519993 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
236568 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
37812 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19446 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17500 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-204830 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-150008 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
461650 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
576045 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-367549 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-452740 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
335000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
150000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
97392 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
133000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
140000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
83849 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
79055 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
72500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
365814 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
362500 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1735 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-90240 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9982 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136990 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8247 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46750 usd
us-gaap Interest Paid Net
InterestPaidNet
8531 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
vism Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest
IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest
590814 usd
vism Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest
IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest
290464 usd
vism Commitment Shares Issued For Financing
CommitmentSharesIssuedForFinancing
0 usd
vism Commitment Shares Issued For Financing
CommitmentSharesIssuedForFinancing
14000 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
0 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
186972 usd
us-gaap Fiscal Period
FiscalPeriod
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fiscal year ends on June 30. References to fiscal year 2024, for example, refer to the fiscal year ending June 30, 2024.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reporting amounts of revenues and expenses during the reported period. Actual results will differ from those estimates. Included in these estimates are assumptions used in Cox, Ross &amp; Rubinstein Binomial Tree stock-based compensation valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate and in the valuation allowance of deferred tax assets and derivative liability.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is subject to a concentration of credit risk from cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash account is held at a financial institution and is insured by the Federal Deposit Insurance Corporation, or FDIC, up to $250,000. As of March 31, 2024 and June 30, 2023, the Company did not exceed these FDIC limits.</p>
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74327012 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6306120 shares
vism Incremental Common Shares Attributable To Common Stock Option
IncrementalCommonSharesAttributableToCommonStockOption
2222 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
5114576 shares
vism Annually Prepaid License Fee
AnnuallyPrepaidLicenseFee
77850 usd
us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
19446 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
57496 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
84246 usd
CY2024Q1 vism Fair Value Of Warrant
FairValueOfWarrant
0 usd
CY2023Q2 vism Fair Value Of Warrant
FairValueOfWarrant
0 usd
CY2024Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
23211 usd
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
80707 usd
CY2024Q1 vism Derivative Liabilities Fair Value Assumptions Exercise Price
DerivativeLiabilitiesFairValueAssumptionsExercisePrice
0.0026
CY2024Q1 vism Derivative Liabilities Fair Value Assumptions Market Price
DerivativeLiabilitiesFairValueAssumptionsMarketPrice
0.0039
CY2023Q1 vism Derivative Liabilities Fair Value Assumptions Market Price
DerivativeLiabilitiesFairValueAssumptionsMarketPrice
0.1945
vism Derivative Liabilities Fair Value Assumptions Expected Volatility Rate
DerivativeLiabilitiesFairValueAssumptionsExpectedVolatilityRate
1.5653 pure
vism Derivative Liabilities Fair Value Assumptions Expected Volatility Rate
DerivativeLiabilitiesFairValueAssumptionsExpectedVolatilityRate
3.033 pure
vism Derivative Liabilities Fair Value Assumptions Risk Free Interest Rate
DerivativeLiabilitiesFairValueAssumptionsRiskFreeInterestRate
0.0548 pure
vism Derivative Liabilities Fair Value Assumptions Risk Free Interest Rate
DerivativeLiabilitiesFairValueAssumptionsRiskFreeInterestRate
0.0479 pure
vism Derivative Liabilities Fair Value Assumptions Expected Term
DerivativeLiabilitiesFairValueAssumptionsExpectedTerm
P60D
vism Expected Dividend Rate
ExpectedDividendRate
0 pure
vism Expected Dividend Rate
ExpectedDividendRate
0 pure
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
548041 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
80707 usd
us-gaap Liability For Future Policy Benefits Period Expense
LiabilityForFuturePolicyBenefitsPeriodExpense
0 usd
vism Loss On Change In Fair Value Of Derivative Liabilities
LossOnChangeInFairValueOfDerivativeLiabilities
-57496 usd
CY2024Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
23211 usd
CY2024Q1 vism Convertible Notes Payable1
ConvertibleNotesPayable1
686908 usd
CY2023Q2 vism Convertible Notes Payable1
ConvertibleNotesPayable1
937576 usd
CY2024Q1 vism Discount On Convertible Notes Payable
DiscountOnConvertibleNotesPayable
-10984 usd
CY2023Q2 vism Discount On Convertible Notes Payable
DiscountOnConvertibleNotesPayable
0 usd
CY2024Q1 vism Convertible Notes Payable To Related Parties Current
ConvertibleNotesPayableToRelatedPartiesCurrent
675924 usd
CY2023Q2 vism Convertible Notes Payable To Related Parties Current
ConvertibleNotesPayableToRelatedPartiesCurrent
937576 usd
CY2024Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
675924 usd
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
937576 usd
vism Scheduleofconvertible Notes Payabletabletextblock
ScheduleofconvertibleNotesPayabletabletextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes payable at June 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">937,576</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes issued during the nine months ended March 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">133,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes repaid in cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(76,250 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Short term loan amended to be convertible note payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Discount related to convertible notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,984 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Conversion of convertible notes payable into common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(331,317 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes payable at March 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">675,924</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
937576 usd
vism Convertible Notes Issued55
ConvertibleNotesIssued55
133000 usd
vism Convertible Notes Repaid In Cash
ConvertibleNotesRepaidInCash
-76250 usd
vism Short Term Loan Amended To Be Convertible Note Payable
ShortTermLoanAmendedToBeConvertibleNotePayable
10000 usd
vism Discount Related To Convertible Notes Payable
DiscountRelatedToConvertibleNotesPayable
-10984 usd
vism Conversion Of Convertible Notes Payable Into Common Stock
ConversionOfConvertibleNotesPayableIntoCommonStock
-331317 usd
CY2024Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
675924 usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
47163371 shares
vism Convertible Notes Payable Principle Amount
ConvertibleNotesPayablePrincipleAmount
331317 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
240257 usd
vism Convertible Notes Payable Conversion Expense
ConvertibleNotesPayableConversionExpense
19250 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
590814 usd
us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.0125
vism Loss On Extinguishments Of Debt Related To Payoff Of Convertible Note
LossOnExtinguishmentsOfDebtRelatedToPayoffOfConvertibleNote
21141 shares
vism Loss On Extinguishment Of Debt Related To Payoff Of Convertible Note
LossOnExtinguishmentOfDebtRelatedToPayoffOfConvertibleNote
-21141 shares
vism Gain On Extinguishment Of Debt Amount
GainOnExtinguishmentOfDebtAmount
-21141 usd
vism Common Stock Convertible Conversion Prices Increase
CommonStockConvertibleConversionPricesIncrease
2.43
vism Dividend Common Stock
DividendCommonStock
630130 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126480567 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126472250 shares
vism Unvested Shares Issued For The Restricted Stock
UnvestedSharesIssuedForTheRestrictedStock
8309 shares
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
519993 usd
us-gaap Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
5048426 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5115207 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.025
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
631 shares
vism Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Warrant
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceWarrant
10.395
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5114576 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.023
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5114576 shares
CY2024Q1 vism Share Based Compensations Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.023
CY2024Q1 vism Class Of Warrants Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights1
0.0169
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5114576 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3DT10H
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.023
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5114576 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.023
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
11852000000 shares
CY2023Q4 us-gaap Share Price
SharePrice
20.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
vism Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0 pure
CY2023 vism Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7297475 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.0536
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
250000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
8309 shares
CY2024Q1 vism Due To Officers Current
DueToOfficersCurrent
178633 usd
vism Accrued Payrolldisclosuretextblock
AccruedPayrolldisclosuretextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 10 - ACCRUED COMPENSATION</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accrued compensation consist of the following at:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023 </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued compensation - officers</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,762</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">900,846</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued compensation - staff</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">750,767</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">471,033</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,833,529</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,371,879</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1833529 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1371879 usd

Files In Submission

Name View Source Status
0001654954-24-006412-index-headers.html Edgar Link pending
0001654954-24-006412-index.html Edgar Link pending
0001654954-24-006412.txt Edgar Link pending
0001654954-24-006412-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vism-20240331.xsd Edgar Link pending
vism_10q.htm Edgar Link pending
vism_10qimg2.jpg Edgar Link pending
vism_ex311.htm Edgar Link pending
vism_ex312.htm Edgar Link pending
vism_ex321.htm Edgar Link pending
vism_ex322.htm Edgar Link pending
vism-20240331_cal.xml Edgar Link unprocessable
vism-20240331_def.xml Edgar Link unprocessable
vism-20240331_lab.xml Edgar Link unprocessable
vism-20240331_pre.xml Edgar Link unprocessable
vism_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable